<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701984</url>
  </required_header>
  <id_info>
    <org_study_id>hysteroscopy</org_study_id>
    <nct_id>NCT03701984</nct_id>
  </id_info>
  <brief_title>The Effect of Intrauterine Lidocaine Infusion and Oral Tramadol on Pain During Diagnostic Office Hysteroscopy</brief_title>
  <official_title>The Effect of Intrauterine Lidocaine Infusion and Oral Tramadol on Pain During Diagnostic Office Hysteroscopy in Postmenopausal Women: Randomized Double-Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of Tramadol and intrauterine
      lidocaine infusion in reducing pain during outpatient diagnostic hysteroscopy in
      postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effectiveness of Tramadol and intrauterine
      lidocaine infusion in reducing pain during outpatient diagnostic hysteroscopy in
      postmenopausal women. Postmenopausal Women undergoing outpatient hysteroscopy in Cairo
      university will be divided into three groups, the first group will receive Tramadol 5mg 1
      hour before the procedure, the second group will receive 20 ml lidocaine in 1000 ml normal
      saline infusion during the procedure, and the third will receive a placebo. A visual analog
      scale will assess pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain perception during the procedure</measure>
    <time_frame>10 minutes after starting the procedure.</time_frame>
    <description>The pain will be assessed using a visual analogue scale(VAS) after inserting the hysteroscope through the cervical canal.VAS of 0 indicates no pain and VAS of 10 indicates the worst possible experienced pain. The pain VAS is self‐completed by the patients. The patients are asked to place a line perpendicular to the VAS line at the point that represents their pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain perception after the procedure</measure>
    <time_frame>10 minutes after the procedure.</time_frame>
    <description>Pain will be assessed using a visual analog scale(VAS) 10 minutes after the procedure.
VAS of 0 indicates no pain and VAS of 10 indicates the worst possible experienced pain.
The pain VAS is self‐completed by the patient. The patients are asked to place a line perpendicular to the VAS line at the point that represents their pain intensity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Hysteroscopy</condition>
  <arm_group>
    <arm_group_label>lidocaine infusion arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tramadol arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).</description>
    <arm_group_label>lidocaine infusion arm</arm_group_label>
    <other_name>lidocaine infusion arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.</description>
    <arm_group_label>tramadol arm</arm_group_label>
    <other_name>tramadol HCL arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>placebo arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal patients with an indication for office hysteroscopy (postmenopausal
             bleeding or abnormal ultrasound findings)

          -  Consent to the procedure

        Exclusion Criteria:

          -  Positive Chlamydia culture.

          -  patients who have an Allergy to local anesthesia or tramadol.

          -  A previous adverse reaction to any of the drugs used in the study.

          -  Patients were receiving any form of analgesia or current use of monoamine oxidase
             inhibitors.

          -  Nulliparous patients and patients with cervical pathology, retroverted uterus
             (detected by transvaginal ultrasound), and previous cervical surgery.

          -  Patients who have severe vaginal bleeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED S ASHOUR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine Cairo university</name>
      <address>
        <city>Giza</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>lecturer in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

